LPAR3 Membrane Protein Introduction

Introduction of LPAR3

LPAR3, also known as endothelial differentiation receptor 2 (EDG2) is a member of G protein-coupling receptor family and EDG subfamily. It is expressed in a lot of human tissues, but highly in specific tissues, such as prostate, testis, heart, urinary bladder and so on. Now most studies are designed to investigate the effect of LPAR3 on pathological process of many diseases and look forward to finding new potential therapeutic strategies for diseases.

Basic Information of LPAR3
Protein Name Lysophosphatidic acid receptor 3
Gene Name LPAR3
Aliases EDG7, GPCR, LPA3, Edg-7, LP-A3, HOFNH30, RP4-678I3
Organism Homo sapiens (Human)
UniProt ID Q9UBY5
Transmembrane Times 7
Length (aa) 353

Function of LPAR3 Membrane Protein

LPAR3 is involved in many biological functions via interacting with lysophosphatidic acid and mediating lysophosphatidic acid-evoked calcium mobilization. Most researches have been proved that LPAR3 is associated with the progression of types of cancers and atherosclerosis. LPAR1/3 antagonism can enhance the percentage of non-inflammatory, monocytes and T-regulatory cells and reduce LDL cholesterol levels, thus lowering atherosclerosis development. Moreover, LPAR3 is involved in the cell proliferation, apoptosis, invasion and migration. LPA stimulates the migration of oral carcinoma cells via LPAR3. In vivo study, the inhibition of LPA receptors can suppress migration and invasion in ovarian cancer cells. And Liao’s study shows LPA-LPA3 signaling pathway stimulates the activation of focal adhesion kinase (FAK) and paxillin, increasing cell motility in human pancreatic cancer cells. These findings also indicate LPA-LPAR3 axis can be considered as the potential therapeutic target for cancer and atherosclerosis. Besides, recent study indicates that LPA-LPAR3 axis is also related to the regulation of obesity via inhibiting insulin signaling in primary rat hepatocytes.

Schematic representation of the signaling pathways activated by the LPA1–6 receptors. Fig.1 Schematic representation of the signaling pathways activated by the LPA1–6 receptors. (González-Gil, 2015)

Application of LPAR3 Membrane Protein in Literature

  1. Zuo C., et al. Osteoglycin attenuates cardiac fibrosis by suppressing cardiac myofibroblast proliferation and migration through antagonizing lysophosphatidic acid 3/matrix metalloproteinase 2/epidermal growth factor receptor signalling. Cardiovascular Research. 2018, 114(5):703-712. PubMed ID: 29415171

    The study shows that osteoglycin (OGN) overexpression can significantly decrease the proliferation and migration of cardiac myofibroblasts (CMFs) and reduce the transactivation of the epidermal growth factor receptor (EGFR). Moreover, OGN interacts with LPA3 to suppress cell surface translocation of membrane type 1 matrix metalloproteinase (MT1-MMP) and subsequent pro-MMP-2 activation in Rho/ROCK-dependent manner, thus reducing EGFR transactivation.

  2. Chen X., et al. Lysophosphatidic acid enhanced the osteogenic and angiogenic capability of osteoblasts via LPA1/3 receptor. Connective Tissue Research. 2018, 16:1-10. PubMed ID: 29447019

    The study indicates that LPA may interact with LPA1/3 and stimulates osteogenesis and angiogenesis capability of pre-osteoblasts, thus providing a novel and effective treatment strategy for bone regeneration success.

  3. Lin K H., et al. Activation of Lysophosphatidic Acid Receptor 3 Inhibits Megakaryopoiesis in Human Hematopoietic Stem Cells and Zebrafish. Stem Cells & Development. 2018, 27(3):216-224. PubMed ID: 29239275

    The study reveals that LPA3 may play a negative role during megakaryopoiesis in human hematopoietic stem cell and zebrafish, thus providing a new therapeutic strategy for megakaryopenia.

  4. Sánchez-Marín L., et al. Systemic blockade of LPA 1/3, lysophosphatidic acid receptors by ki16425 modulates the effects of ethanol on the brain and behavior. Neuropharmacology. 2018, 133:189-201. PubMed ID: 29378212

    The study suggests that LPA1/3 receptor antagonists might be a potential new class of drugs that are suitable for treating or preventing alcohol use disorders.

  5. Fukushima K., et al. Lysophosphatidic acid signaling via LPA1 and LPA3 regulates cellular functions during tumor progression in pancreatic cancer cells. Experimental Cell Research. 2017, 352(1):139-145. PubMed ID: 28189636

    The study uncovers that LPA signaling via LPA1 and LPA3 may be involved in the regulation of pancreatic cancer cells motile and invasive activities during tumor progression.

LPAR3 Preparation Options

Based on the versatile Magic™ membrane protein production platform, Creative Biolabs can provide many flexible options for soluble and functional target protein, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-LPAR3 antibody development services.

As a forward-looking research institute as well as a leading custom service provider in the field of membrane protein, Creative Biolabs has won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects including generation of many functional membrane proteins. Please feel free to contact us for more information.


  1. González-Gil I, et al. (2015). The status of the lysophosphatidic acid receptor type 1 (LPA1R). Med Chem Commun. 6(1), 13-23.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry


Call us at:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us